The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksVela Technologies Regulatory News (VELA)

Share Price Information for Vela Technologies (VELA)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.012
Bid: 0.011
Ask: 0.013
Change: 0.00 (0.00%)
Spread: 0.002 (18.182%)
Open: 0.012
High: 0.012
Low: 0.012
Prev. Close: 0.012
VELA Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Quarterly Investment Update

23 Feb 2024 12:15

RNS Number : 3086E
Vela Technologies PLC
23 February 2024
 

23 February 2024

Vela Technologies plc

("Vela" or "the Company")

Quarterly Investment Update

The Board of Vela (AIM:VELA), an AIM-quoted investing company focused on early-stage and pre-IPO disruptive technology investments, is pleased to report an update for the quarter ended 31 December 2023.

Key numbers as at 31 December 2023*

· The value of Vela's total assets (including cash) decreased during the quarter by £639,000 (9%) to £6,180,000 (quarter to 30 September 2023 - increase of £942,000 to £6,819,000 (16%)).

· Vela's portfolio comprised a total of 15 active investments (30 September 2023 - 15). Two of these investments were unquoted, thirteen were quoted.

· The investment in St George's Street Capital Limited, which was sold during the quarter under review to Conduit Pharmaceuticals Inc. ("Conduit") in exchange for 1,015,760 Conduit shares, was previously held in the balance sheet as a financial asset in prior quarters and is now held as an asset held for resale in line with other investments already held.

· The fair value of the investment portfolio was £6,174,000 (30 September 2023 - £6,789,000).

· The change in the value of the investment portfolio reflects the disposal of investments valued at c.£40,000 at 30 September 2023 (generating a realised loss of £3,000) and a net unrealised decrease in the fair value of the investment portfolio of £575,000 (quarter to 30 September 2023 - an unrealised gain of £1,043,000).

· Vela's cash balance stood at £6,000 as at 31 December 2023 (30 September 2023 - £30,000). Vela's cash balance as at today's date is c. £60,000.

\* The figures contained within this quarterly investment update are taken from unaudited management information.

Investments traded on a recognised stock market are valued using the accounting policies outlined in the notes to the annual financial statements. Unlisted investments and other financial assets are stated at the values attributed to them in the audited balance sheet as at 31 March 2023, unless there has been a transaction since that date which suggests a materially different valuation.

Key developments in the quarter

· The 2023 Annual General Meeting was held on 11 December 2023 at the Company's registered office. The financial statements for the year ended 31 March 2023 were approved and all other resolutions passed.

· 50,000 shares in EnSilica plc ("EnSilica") were sold, generating gross proceeds of £33,000.

· 300,000 shares in Kanabo Group plc ("Kanabo") were sold, generating gross proceeds of £4,000.

· On 30 November 2023 Vela exercised its put option to sell its economic interest in AZD1656 to Conduit in exchange for 1,015,760 Conduit shares.

· The Company announced its interim results for the half year ended 30 September 2023 on 22 December 2023.

Events since the end of the quarter

· The Company has sold 85,902 shares in Cornerstone FS plc ("Cornerstone"), generating net proceeds of £27,000.

· The Company has sold 45,000 shares in EnSilica generating net proceeds of £22,000.

· The Company sold its remaining 357,692 shares held in Kanabo generating net proceeds of £9,000.

Investment portfolio

At 31 December 2023 the Company's portfolio of investments was valued at £6,174,000 and comprised equity interests in the following 15 companies:

· Aeristech Limited

· Community Social Investment Limited

· Conduit Pharmaceuticals Inc.

· Cornerstone FS PLC

· Ethernity Networks Ltd

· EnSilica plc

· Igraine PLC

· Kanabo Group Plc

· MTI Wireless Edge Ltd.

· Northcoders Group plc

· R8 Capital Investments PLC (formerly Mode Global Holdings plc)

· Rural Broadband Solutions PLC

· Skillcast Group plc

· Tribe Technology Group PLC

· TruSpine Technologies plc

Key developments in investee companies in the quarter

· Cornerstone reported strong trading momentum and adjusted EBITDA ahead of board expectations.

· Tribe Technology Group PLC entered into a £3 million secured term loan facility with Beach Point Capital.

· TruSpine Technologies Plc reported that the company's intellectual property had been successfully registered, on the back of which it hoped to secure a 'substantial fundraise'.

· Kanabo announced it had entered a partnership with British Cannabis to supply CBD to patients via a prescription service.

· MTI Wireless Edge Ltd. reported a contract win with orders worth approximately US$1 million, to be supplied over the following 14 months; and third quarter results showing improvements in all key performance indicators, notwithstanding events in Israel.

· The shares of R8 Capital Investments PLC (formerly Mode Global Holdings plc) were suspended from trading on the announcement of a proposed reverse takeover of Redwood Financial Partners Limited. The parties have set a target date for completion of 1 July 2024.

· EnSilica published its results for the year ended 31 May 2023. These showed improved numbers compared to the previous year, a trend repeated in its trading update for the subsequent half year. EnSilica also announced a placing of £1.56 million which was prompted by the need to finance ever-increasing new business opportunities.

Other activities

· Since the publication of the last quarterly update in December 2023, the Board of Vela has spoken or met with representatives of the following investee companies:

Community Social Investment Limited

Conduit Pharmaceuticals Inc.

TruSpine Technologies plc

· In May 2023 Vela's Board was approached by a third party with a proposal to inject additional equity capital of up to £15 million, which were on terms acceptable to the Board, and to amend the Company's investing policy so as to concentrate on the life sciences sector. Such a transaction would have been transformative for Vela. The Board accordingly expended considerable time and effort in pursuing this proposal; incurring costs in excess of £50,000 with its professional advisers. Unfortunately, despite numerous discussions and meetings spread over many months, the third party was unable to secure the minimum funds necessary to complete the proposed investment. Discussions were terminated in early January 2024. The intention of the Board is to settle £50,000 of costs incurred in relation to the aborted transaction through the issue of new ordinary shares in the Company in due course. The Company continues to appraise investment proposals in accordance with its current investing policy.

Executive Director, James Normand, commented:

"Much of the £900,000+ leap forward in the value of Vela's investment portfolio in the September quarter has been reversed in the December quarter. Vela's investment in EnSilica, a highly rated business, perversely fell in value by a third (though it has since recovered a good part of that drop), while Conduit's value is similarly a fraction of the price at which it listed in September. Vela's performance and position remains impeded by the continued lack of confidence in the public markets generally, particularly in the small cap markets in which Vela is largely invested. Although Vela's investments are for the most part in listed stocks, there is little activity in these stocks and so their market values do not reflect our opinion of their true worth."

For further information, please contact:

Vela Technologies plc

Brent Fitzpatrick, Non-Executive Chairman

James Normand, Executive Director

 

Tel: +44 (0) 7421 728875

Allenby Capital Limited (Nominated Adviser)

Tel: +44 (0) 20 3328 5656

Nick Athanas / Piers Shimwell

 

Peterhouse Capital Limited (Broker)

Tel: +44 (0) 20 7469 0930

Lucy Williams / Duncan Vasey / Eran Zucker

 

Novus Communications (PR and IR Adviser)

Tel: +44 (0) 20 7448 9839

Alan Green / Jacqueline Briscoe

 

 

About Vela Technologies

Vela Technologies plc (AIM: VELA) is an investing company focused on early stage and pre-IPO long term disruptive technology investments.?Vela's investee companies have either developed ways of utilising technology or are developing technology with a view to disrupting the businesses or sector in which they operate. Vela Technologies will also invest in already-listed companies where valuations offer additional opportunities.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDFLFLFFSIVFIS
Date   Source Headline
26th Mar 20247:00 amRNSIssue of Equity
26th Feb 20241:21 pmRNSHolding in Company
23rd Feb 202412:15 pmRNSQuarterly Investment Update
8th Jan 202411:49 amRNSHolding(s) in Company
22nd Dec 20237:00 amRNSInterim Results
13th Dec 20237:00 amRNSQuarterly Investment Update
11th Dec 20232:19 pmRNSResult of AGM
5th Dec 202311:04 amRNSHolding in Company
1st Dec 20233:02 pmRNSExercise of Put Option
17th Nov 20238:58 amRNSNotice of AGM
28th Sep 20237:00 amRNSFinal results for the year ended 31 March 2023
27th Sep 20237:00 amRNSQuarterly Investment Update
21st Sep 20239:01 amRNSUpdate re. Economic Interest in AZD1656
8th Sep 20233:18 pmRNSFurther update re. Economic Interest in AZD1656
7th Sep 20237:00 amRNSUpdate re. Economic Interest in AZD1656
5th Sep 20238:50 amRNSUpdate on investment in Tribe Technology Group
15th Aug 20237:00 amRNSUpdate re. Economic Interest in AZD1656
12th Jun 202311:11 amRNSHolding in Company
6th Jun 20237:00 amRNSQuarterly Investment Update
23rd May 202311:45 amRNSInvestment in Tribe Technology Group Limited
15th May 20231:23 pmRNSUpdate re. Economic Interest in AZD1656
20th Apr 20233:01 pmRNSOption for potential sale of interest in AZD1656
14th Mar 20232:57 pmRNSInvestment in EnSilica plc
10th Feb 20237:00 amRNSQuarterly Investment Update
20th Jan 202312:27 pmRNSInvestment in Ethernity Networks Ltd
15th Dec 20227:00 amRNSInterim Results
6th Dec 20227:00 amRNSUpdate re. investment in EnSilica
28th Nov 20227:00 amRNSFurther investment in Northcoders Group plc
9th Nov 20229:00 amRNSUpdate re. AZD1656
8th Nov 20227:00 amRNSQuarterly Investment Update
25th Oct 202212:49 pmRNSResult of AGM
20th Oct 20221:52 pmRNSHolding(s) in Company
20th Oct 20227:52 amRNSBoard Change
28th Sep 20227:00 amRNSFinal results for the year ended 31 March 2022
2nd Sep 20227:40 amRNSStrategic Update
18th Aug 20229:53 amRNSUpdate re. St George Street Capital COVID-19 trial
22nd Jul 20227:00 amRNSQuarterly Investment Update
21st Jul 20221:40 pmRNSAppointment of Non-Executive Director
11th Jul 20227:00 amRNSHolding in Company
6th Jul 202212:07 pmRNSUpdate on investment - Community Social Investment
1st Jul 20221:27 pmRNSHolding(s) in Company
23rd Jun 202212:28 pmRNSInvestment in TruSpine Technologies plc
14th Jun 202212:49 pmRNSFurther update re TruSpine Technologies plc
14th Jun 20227:00 amRNSStatement re. potential investment in TruSpine
19th May 20221:26 pmRNSUpdate re. investment in EnSilica
3rd May 20227:00 amRNSQuarterly Investment Update and Change of Broker
26th Apr 20227:00 amRNSAppointment of PR and IR Adviser
30th Mar 20221:15 pmRNSAcquisition of a 28.8% interest in Igraine plc
7th Mar 20227:15 amRNSUpdate re. St George Street Capital COVID-19 trial
8th Feb 20221:30 pmRNSTR-1:Notification of major holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.